Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity.
Saved in:
| Title: | Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity. |
|---|---|
| Authors: | Nakayama M; Core Research Laboratories, Bio‑Pharmaceutical Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan., Takagi-Maeda S; Project and Product Management Group 3, CMC Development, Manufacturing, Kyowa Kirin Co., Ltd., Tokyo 100‑0004, Japan., Machino Y; Project and Product Management Group 3, CMC Development, Manufacturing, Kyowa Kirin Co., Ltd., Tokyo 100‑0004, Japan., Nihira K; Global Operational Transformation Kyowa Kirin International Plc., Marlow SL7 1HZ, UK., Inoue M; Innovation Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan., Takahashi N; Innovation Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan., Usami K; Innovation Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan. |
| Source: | Oncology reports [Oncol Rep] 2025 Nov; Vol. 54 (5). Date of Electronic Publication: 2025 Sep 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1791-2431 |
|---|---|
| DOI: | 10.3892/or.2025.8988 |
